TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00750009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Patients receive a tailored intervention or generic information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Patients receive a tailored intervention or generic information
Study: NCT00343642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active fructo-oligosaccharide
Description: 2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fructo-oligosaccharide
Description: 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
Study: NCT03047447

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome
Description: 30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome
Description: 30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome
Description: 30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
Study: NCT00390052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV and orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT00512759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goal-directed preload and afterload decrement
Description: Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
Study: NCT00855829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miniature Actilady device active
Description: Devices: Targeted pressure waves are created by two kind of methods ActiLady).~1. The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~2. Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Miniature Actilady device not active
Description: Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves.
Study: NCT02599792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kalydeco
Study: NCT03037385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralsetinib (BLU-667)
Description: pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralsetinib (BLU-667)
Description: pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
Study: NCT01337089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Study: NCT02194049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT04269772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE
Description: Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Treatment as usual, unrestricted, as provided by prison and community providers.
Study: NCT02842060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myDEx
Description: myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NTHP
Description: The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
Study: NCT00216125

Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: Etoposide 50 mg/m2, days 1-5, 29-33
Study: NCT03171025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
Study: NCT00343642

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
Study: NCT01203189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole 2% foam
Description: Subjects in the Foam (F) group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole 2% foam
Description: Subjects in the Foam (F) group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole 2% shampoo
Description: Subjects in the Shampoo (S) group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole 2% shampoo
Description: Subjects in the Shampoo (S) group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
Study: NCT01822652

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: iC9-GD2 T Cells - frozen
Description: Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~* Dose Level 1 = 1 x 10\^7~* Dose Level 2 = 1 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: iC9-GD2 T Cells - fresh
Description: For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1 x 10\^8~* Dose Level 2 = 1.5 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.
Study: NCT00216125

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Radiation 5940 cGy (180 cGy/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel 75mg/m2 q3wk x 3 cycles
Study: NCT00656656

Intervention type: DRUG
Group type: OTHER
Intervention: Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
Description: Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks~Rituximab: 1000 mg i.v. given twice at a 2-week interval~Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks~Azathioprine: 2.5 mg/kg body weight daily p.o.
Study: NCT01822652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide (500 mg/m2/day x 2 days, for patients \<12 kg = 16.7 mg/kg/day x 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: Fludarabine (30 mg/m2/day x 3 days, for patients \<12 kg = 1 mg/kg/day x 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Pembrolizumab (2 mg/kg on Day -1 and on Day 21).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: iC9-GD2 T cells
Description: For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1.5 x 10\^8~* Dose Level 2 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks.
Study: NCT02062502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™ New Seed Process
Description: Varicella virus vaccine live manufactured with a new seed process

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX™ 2007 process
Description: Varicella virus vaccine live manufactured with the 2007 process

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II™
Description: Measles, Mumps, and Rubella virus vaccine live

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II™
Description: Measles, Mumps, and Rubella virus vaccine live
Study: NCT04411108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaia Back Pain App
Description: The Kaia Back Pain App provides instructions on exercise execution to participants for one week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapist Exercise Instructions and written handouts
Description: Participants will be instructed by physiotherapists in exercise execution and receive handouts and exercise for one week
Study: NCT06282627

Intervention type: OTHER
Intervention: Observational study
Description: No intervention. Observational study
Study: NCT00587873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: 5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Thioguanine
Description: 6-TG 300 mg/m2 PO as a single oral dose
Study: NCT03041415

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ALED Alone Physical Activity Program
Description: • 12-week class focused on teaching self-regulatory skills to increase regular PA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALED + Our Voice PA Program
Description: * 12-week class focused on teaching self-regulatory skills to increase regular PA~* Neighborhood assessment, consensus-building, \& advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity
Study: NCT03203213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sampling of a few drops of blood, lock of hair and urine
Description: Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
Study: NCT03985423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab-Lzsg
Description: Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day \[SD\] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
Study: NCT03119766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kolofort
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT02188017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar gel
Description: Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar gel
Description: Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
Study: NCT01201434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-25 probiotic
Description: 2 tablets per day for 6 months
Study: NCT01017406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSU heel cushion and plantar fascia specific stretching exercise
Description: * Wear heel cushion during daily activity~* Plantar fascia stretching exercise 3 times per day
Study: NCT00967850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Injection
Description: Intravitreal injection of 1,25 mg in 0,05 ml
Study: NCT03205878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecoaching
Description: Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.~Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Patients will receive CPAP according to standard care
Study: NCT00967850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy (Visudyne)
Description: Photodynamic therapy on day 1 as described in standard clinical guidelines.
Study: NCT03836053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 420
Description: 28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
Study: NCT01863680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-1620
Description: The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent \[%\] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
Study: NCT04244994

Intervention type: DEVICE
Group type: OTHER
Intervention: Aptima-Combo2 and Aptima Mgen
Description: Self-taken penile meatal swabs versus first-catch urine samples for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
Study: NCT01863680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analogue
Description: Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH)
Description: Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
Study: NCT04000906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
Study: NCT01980316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-argatroban treated group
Description: Patients in control group will receive Unfractionated heparin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-argatroban treated group
Description: Patients in control group will receive Unfractionated heparin treatment
Study: NCT03352219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reality Check

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity Attention Control
Study: NCT04268784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Single and repeating oral dose(s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single and repeating oral dose(s)
Study: NCT04000906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 10.5 mg/m2
Study: NCT01094873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection
Study: NCT02707055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Ghrelin Receptor Inverse Agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-05190457
Description: Ghrelin Receptor Inverse Agonist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02794493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Formula LC09

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04433169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans Retinoic Acid
Description: ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEGFR inhibitor
Description: VEGFR inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: chemotherapy
Study: NCT01094873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut
Description: Genetic vaccines against Hepatitis C virus infection
Study: NCT04367168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
Study: NCT03556657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
Study: NCT00736242

Intervention type: BIOLOGICAL
Intervention: PEG-IFN alfa-2b
Description: Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling

Intervention type: DRUG
Intervention: RBV
Description: Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling